featured
Apatinib Plus Pegylated Liposomal Doxorubicin vs Pegylated Liposomal Doxorubicin Alone for Platinum-Resistant Recurrent Ovarian Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
JAMA Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Effect of Apatinib Plus Pegylated Liposomal Doxorubicin vs Pegylated Liposomal Doxorubicin Alone on Platinum-Resistant Recurrent Ovarian Cancer: The APPROVE Randomized Clinical Trial
JAMA Oncol 2022 Jun 30;[EPub Ahead of Print], T Wang, J Tang, H Yang, R Yin, J Zhang, Q Zhou, Z Liu, L Cao, L Li, Y Huang, K Jiang, W Wang, F She, N Guan, Z Hou, N Li, L WuFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.